Haisco innovative drugs included in national medical insurance catalog

Haisco Pharmaceutical Group announced today that its class 1 innovative drugs, Tabafenol Injection and Anruikfen Injection, have been included in the National Medical Insurance Catalog (2025 Edition). Tabafenol Injection successfully renewed its inclusion, while Anruikfen Injection was newly added, effective from January 1, 2026, to December 31, 2027.

Tabafenol Injection is indicated for sedation and anesthesia in non-intubated surgical/procedural settings, general anesthesia induction and maintenance, and sedation during mechanical ventilation in intensive care. Anruikfen Injection is approved for mild to moderate post-abdominal surgery pain. These inclusions are expected to significantly benefit the market promotion and future sales of these innovative drug products.

The company currently has four class 1 innovative drugs, including Tabafenol Injection, Anruikfen Injection, Benzene Sulfonate Cligabalin Capsules, and Coglitine Tablets, listed in the 2025 National Medical Insurance Catalog. The company notes that while the inclusion is beneficial for long-term growth, it is not expected to have a major impact on short-term operating performance.